Overexpression of HILPDA, but not DGAT1/2, is associated with shorter overall survival in pancreatic cancer patients (Fig. 3a), suggesting that additional roles of HILPDA, other than regulating triacylglyceride (TAG) synthesis, may influence the outcome of pancreatic cancer patients. Here, DGAT1 is linked to pancreatic neoplasm.